Section Arrow
Quote
GH.NASDAQ
- Guardant Health
Quotes are at least 15-min delayed:2025/09/18 14:04 EDT
Regular Hours
Last
 58.36
+1.17 (+2.05%)
Day High 
58.65 
Prev. Close
57.19 
1-M High
68 
Volume 
786.49K 
Bid
58.33
Ask
58.4
Day Low
56.95 
Open
57.17 
1-M Low
53.4 
Market Cap 
7.13B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 57.67 
20-SMA 60.51 
50-SMA 53.8 
52-W High 68 
52-W Low 20.14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.35/-2.23
Enterprise Value
8.44B
Balance Sheet
Book Value Per Share
-2.45
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
739.02M
Operating Revenue Per Share
4.30
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BIAFbioAffinity Technologies0.16915-0.01345-7.37%-- 
NEOGNeogen Corp5.675+0.215+3.94%879PE
ISPCiSpecimen Inc1.4402-0.1598-9.99%-- 
DHRDanaher Corp194.305+1.365+0.71%40.96PE
OPKOPKO Health1.465+0.075+5.40%-- 
Quotes are at least 15-min delayed：2025/09/18 14:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD,test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.